1.
Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value Health. 2018;21(9):1054-1061. doi:10.1016/j.jval.2018.06.013.
1.
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017;136(23):2210-2219. doi:10.1161/CIRCULATIONAHA.117.028430.
1.
Cao J, Perez-Pinera P, Lowenhaupt K, et al. Versatile and on-demand biologics co-production in yeast. Nat Commun. 2018;9(1):77. doi:10.1038/s41467-017-02587-w.
1.
Zecha J, Satpathy S, Kanashova T, et al. TMT Labeling for the Masses: A Robust and Cost-efficient, In-solution Labeling Approach. Mol Cell Proteomics. 2019;18(7):1468-1478. doi:10.1074/mcp.TIR119.001385.
1.
Christensen KD, Vassy JL, Phillips KA, et al. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018;20(12):1544-1553. doi:10.1038/gim.2018.35.
1.
Rohland N, Reich D. Cost-effective, high-throughput DNA sequencing libraries for multiplexed target capture. Genome Res. 2012;22(5):939-46. doi:10.1101/gr.128124.111.
1.
Gomes ALC, Galagan JE, Segrè D. Resource competition may lead to effective treatment of antibiotic resistant infections. PLoS One. 2013;8(12):e80775. doi:10.1371/journal.pone.0080775.
1.
Hyman SE. The unconscionable gap between what we know and what we do. Sci Transl Med. 2014;6(253):253cm9. doi:10.1126/scitranslmed.3010312.